GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Pml | affects localization | ISO | PML (Homo sapiens) | 6480464 | CTD | Tretinoin affects the localization of PML protein | PMID:9834237 | Pml | decreases expression | ISO | PML (Homo sapiens) | 6480464 | CTD | Tretinoin results in decreased expression of PML mRNA | PMID:16249480 | Pml | increases cleavage | ISO | PML (Homo sapiens) | 6480464 | CTD | Tretinoin results in increased cleavage of PML protein mutant form | PMID:12130515 | Pml | increases degradation | ISO | PML (Homo sapiens) | 6480464 | CTD | Tretinoin results in increased degradation of PML protein mutant form | PMID:15748426 PMID:16352814 PMID:17217047 PMID:19029980 PMID:9834237 | Pml | increases expression | ISO | PML (Homo sapiens) | 6480464 | CTD | Tretinoin results in increased expression of PML mRNA; Tretinoin results in increased expression of PML protein | PMID:12015078 PMID:33167477 | Pml | increases phosphorylation | ISO | PML (Homo sapiens) | 6480464 | CTD | Tretinoin results in increased phosphorylation of PML protein mutant form | PMID:19029980 | Pml | increases response to substance | ISO | PML (Homo sapiens) | 6480464 | CTD | PML protein mutant form results in increased susceptibility to Tretinoin | PMID:32929351 | Pml | multiple interactions | ISO | PML (Homo sapiens) | 6480464 | CTD | [PML protein mutant form results in increased susceptibility to Tretinoin] which results in increased abundance of and results in increased secretion of Triglycerides; [Tretinoin co-treated with Arsenic Trioxide] results in decreased expression of PML mRNA alternative form; [Tretinoin co-treated with Arsenic Trioxide] results in increased degradation of PML protein mutant form; [Tretinoin co-treated with Butyrates] results in increased cleavage of PML protein mutant form; [Tretinoin co-treated with hexamethylene bisacetamide] results in increased cleavage of PML protein mutant form; PML gene mutant form results in decreased susceptibility to [Arsenic Trioxide co-treated with Tretinoin]; Tretinoin inhibits the reaction [CCNH protein binds to and results in increased phosphorylation of PML protein mutant form]; Tretinoin inhibits the reaction [PML protein mutant form results in decreased expression of SPI1 mRNA]; Tretinoin inhibits the reaction [PML protein mutant form results in decreased expression of SPI1 protein]; Tretinoin results in increased degradation of [PML protein mutant form binds to RARA protein mutant form] | PMID:12130515 PMID:16352814 PMID:16935935 PMID:19225113 PMID:26285909 PMID:28130038 PMID:32929351 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |